Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
复制标题
DOI：
10.1186/1476-4598-8-105
复制
发表时间：
2009-11-17
期刊：
影响因子：
37.3
通讯作者：
Zhong, Xiao Yan
中科院分区：
文献类型：
--
作者：
Kohler, Corina;Radpour, Ramin;Zhong, Xiao Yan
背景资料：为了简化癌症管理，癌症研究最近越来越致力于发现和开发非侵入性生物标志物。在这方面，循环无细胞DNA（ccf DNA）似乎是一个有前途的候选人。改变的ccf核DNA（nDNA）和线粒体DNA（mtDNA）的水平已被发现在几种癌症类型，并可能有诊断value.Methods：使用多重实时PCR，我们调查了ccf的nDNA和mtDNA的水平，从恶性和良性乳腺肿瘤患者的血浆样本，并从健康对照。为了评估血浆ccf nDNA和mtDNA作为区分三个研究组的生物标志物的适用性，我们进行了ROC（受试者工作特征）曲线分析。结果：恶性肿瘤组ccf nDNA表达水平明显高于良性肿瘤组（P < 0. 05），而良性肿瘤组ccf nDNA表达水平明显高于恶性肿瘤组（P < 0. 05与健康对照组比较，P < 0.001良性组和恶性组ccf mtDNA水平均显著低于良性组（P <0.001; P = 0.022）。ccf nDNA水平与肿瘤大小（< 2 cm vs. >2cm）有关
Background: With the aim to simplify cancer management, cancer research lately dedicated itself more and more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have a diagnostic value.Methods: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing between the three study-groups we performed ROC (Receiver Operating Characteristic) curve analysis. We also compared the levels of both species in the cancer group with clinicopathological parameters.Results: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022). The level of ccf nDNA was also associated with tumor-size (< 2 cm vs. >2 cm